New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:40 EDTGTXIGTx to present GTx-758 Phase 2 clinical trial preliminary findings
GTx announced that it will present preliminary findings from the company’s Phase 2 clinical trial evaluating GTx-758. The Phase 2 clinical trial is sequentially testing for safety and effectiveness of 125mg oral daily dose and 250mg oral daily dose of GTx-758 as secondary hormonal therapy in men with CRPC. The goal of the Phase 2 trial is to show that lower doses of GTx-758 are well tolerated and effective in reducing free testosterone and, in greater than 50% of subjects, achieving a 50% reduction of serum prostate specific antigen by Day 90. Preliminary data shows that a majority of subjects who were experiencing hot flashes prior to taking GTx-758 have reported improvement in and/or stabilization of their hot flashes and bone turnover biomarkers have decreased in a majority of the patients. As for safety, GTx-758 continues to be well tolerated, with no reported venous thromboembolic events or deaths.
News For GTXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:16 EDTGTXIGTx enters into worldwide license agreement with UTRF
GTx, Inc. announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation, or UTRF, to develop its proprietary selective androgen receptor degrader technology which potentially can degrade and inhibit all forms of androgen receptor, including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer.
April 13, 2015
17:25 EDTGTXIFormanek reports 5.1% passive stake in GTx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use